<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02874703</url>
  </required_header>
  <id_info>
    <org_study_id>2015P000200</org_study_id>
    <nct_id>NCT02874703</nct_id>
  </id_info>
  <brief_title>Mechanisms of Diastolic Dysfunction Among Persons With HIV Compared With Non-HIV Control Subjects</brief_title>
  <official_title>Mechanisms of Diastolic Dysfunction Among Persons With HIV Compared With Non-HIV Control Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>President and Fellows of Harvard College</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nutrition Obesity Research Center at Harvard</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <brief_summary>
    <textblock>
      In this study, investigators plan to test two potential mechanisms contributing to diastolic&#xD;
      dysfunction among asymptomatic persons with HIV who are on cART. The first proposed mechanism&#xD;
      is that heightened systemic immune activation/inflammation in HIV contributes to myocardial&#xD;
      inflammation, which in turn promotes myocardial fibrosis. The second mechanism is that&#xD;
      ectopic fat deposition (increased visceral adiposity) in HIV relates to increased&#xD;
      intramyocardial lipid content, which in turn contributes to diastolic dysfunction. Both HIV&#xD;
      positive and HIV-negative participants will undergo cardiac MRI/ MRS imaging studies for&#xD;
      evaluation of myocardial fibrosis, myocardial inflammation, and intramyocardial lipid&#xD;
      content. Traditional markers of CVD risk, inflammatory markers/immune, hormonal markers, and&#xD;
      markers of myocardial stretch/injury will be assessed in relation to cardiac MRI/MRS&#xD;
      outcomes. Additionally, a small subset of participants with HIV will undergo longitudinal&#xD;
      evaluations to assess effects of a clinically prescribed hormonal therapy on myocardial&#xD;
      structure and function.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Actual">August 2019</completion_date>
  <primary_completion_date type="Actual">August 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Extracellular Volume (ECV), a measure of myocardial fibrosis on Cardiac MRI</measure>
    <time_frame>3 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Myocardial Inflammation on Cardiac MRI</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intramyocardial fat on Cardiac MRI/MRS</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic function on Cardiac MRI</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visceral Adiposity on MRI</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation/ immune markers</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hormonal markers</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Markers of myocardial stretch</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">48</enrollment>
  <condition>HIV</condition>
  <condition>Diastolic Dysfunction</condition>
  <condition>Myocardial Fibrosis</condition>
  <arm_group>
    <arm_group_label>HIV-positive</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>HIV-negative</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cardiac MRI/MRS</intervention_name>
    <arm_group_label>HIV-negative</arm_group_label>
    <arm_group_label>HIV-positive</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood, plasma and serum&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        HIV positive and HIV negative participants&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        HIV positive subjects&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  age ≥40 and ≤75 years&#xD;
&#xD;
          -  documented HIV infection&#xD;
&#xD;
          -  participant report that combination antiretroviral therapy (cART) (any regimen) has&#xD;
             been taken stably without &gt; 4 week interruption for at least 180 days prior to study&#xD;
             entry (report of switching regimens in that time frame is permissible)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  CD4 &lt; 100 cell/mm3&#xD;
&#xD;
          -  current active AIDS-defining illness&#xD;
&#xD;
          -  current active or recent (not fully resolved within 30 days prior to study entry)&#xD;
             systemic bacterial, fungal, parasitic, or viral infections (except HIV, HBV, human&#xD;
             papillomavirus [HPV], or HCV)&#xD;
&#xD;
          -  current active cancer&#xD;
&#xD;
          -  clinical ASCVD, as defined by 2013 ACC/AHA guidelines (including previous diagnosis of&#xD;
             AMI, ACS, stable or unstable angina, coronary or other arterial revascularization,&#xD;
             stroke, TIA, PAD), by subject report&#xD;
&#xD;
          -  clinical diagnosis of HFpEF or HFrEF, by subject report&#xD;
&#xD;
          -  diagnosed DM on antihyperglycemic medication&#xD;
&#xD;
          -  current, active use of immune suppressant medication including oral or intravenous&#xD;
             corticosteroid or injectable biologic (oral ASA or NSAID use permitted)&#xD;
&#xD;
          -  eGFR &lt;45 ml/min/1.73 m2 calculated by CDK-EPI&#xD;
&#xD;
          -  standard contraindications to MRI procedure based on MGH MRI Patient Procedure&#xD;
             Screening Form - including history of severe allergy to gadolinium&#xD;
&#xD;
          -  use of lipid lowering agents including statin drugs, fibrates, ezetimibe, red yeast&#xD;
             rice, niacin or omega-3 fatty acids (&gt;3 grams/day in standalone formulations) in the&#xD;
             90 days prior to study entry&#xD;
&#xD;
          -  use of ACE inhibitor, ARB, or aldosterone receptor blocker in the 90 days prior to&#xD;
             study entry&#xD;
&#xD;
          -  pregnancy or breastfeeding (female subjects of reproductive potential)&#xD;
&#xD;
          -  other medical, psychiatric, or psychological condition that, in the opinion of the&#xD;
             study investigator, would interfere with completion of study procedures&#xD;
&#xD;
        HIV negative subjects:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
        • age ≥40 and ≤75 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  HIV infection&#xD;
&#xD;
          -  current active or recent (not fully resolved within 30 days prior to study entry)&#xD;
             systemic bacterial, fungal, parasitic, or viral infections (except HIV, HBV, human&#xD;
             papillomavirus [HPV], or HCV)&#xD;
&#xD;
          -  current active cancer&#xD;
&#xD;
          -  clinical ASCVD, as defined by 2013 ACC/AHA guidelines (including previous diagnosis of&#xD;
             AMI, ACS, stable or unstable angina, coronary or other arterial revascularization,&#xD;
             stroke, TIA, PAD), by subject report&#xD;
&#xD;
          -  clinical diagnosis of HFpEF or HFrEF, by subject report&#xD;
&#xD;
          -  diagnosed DM on antihyperglycemic medication&#xD;
&#xD;
          -  current, active use of immune suppressant medication including oral or intravenous&#xD;
             corticosteroid or injectable biologic (oral ASA or NSAID use permitted)&#xD;
&#xD;
          -  eGFR &lt;45 ml/min/1.73 m2 calculated by CDK-EPI&#xD;
&#xD;
          -  standard contraindications to MRI procedure based on MGH MRI Patient Procedure&#xD;
             Screening Form - including history of severe allergy to gadolinium&#xD;
&#xD;
          -  use of lipid lowering agents including statin drugs, fibrates, ezetimibe, red yeast&#xD;
             rice, niacin or omega-3 fatty acids (&gt;3 grams/day in standalone formulations) in the&#xD;
             90 days prior to study entry&#xD;
&#xD;
          -  use of ACE inhibitor, ARB, or aldosterone receptor blocker in the 90 days prior to&#xD;
             study entry&#xD;
&#xD;
          -  pregnancy or breastfeeding (female subjects of reproductive potential)&#xD;
&#xD;
          -  other medical, psychiatric, or psychological condition that, in the opinion of the&#xD;
             study investigator, would interfere with completion of study procedures&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>August 12, 2016</study_first_submitted>
  <study_first_submitted_qc>August 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 22, 2016</study_first_posted>
  <last_update_submitted>October 11, 2019</last_update_submitted>
  <last_update_submitted_qc>October 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Tomas Neilan, MD</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

